Is Anticoagulation Antiarrhythmic?* Stanley Nattel, MD A trial fibrillation (AF) is a highly prevalent clinical problem that is becoming more common with population aging, and presents a broad range of therapeutic challenges (1, 2 ).
An improved understanding of the underlying pathophysiology is central to improving management options for the arrhythmia (3).
The most significant complication of AF is thromboembolism, particularly stroke (4) . AF-related stroke is effectively prevented by oral anticoagulation (OAC), achieved traditionally by vitamin K antagonists (VKAs) such as warfarin, and more recently by direct-acting agents (DOACs) such as the thrombinantagonist dabigatran and the Factor Xa (FXa) inhibitors rivaroxaban, apixaban, and edoxaban (4) .
Because of the attendant bleeding risk, OAC therapy has been targeted to patients with elevated stroke risk, although with the reduced bleeding seen with DOACs versus VKAs, the threshold for OAC therapy has decreased and the emphasis has shifted to identifying true low-risk individuals who may safely be managed without OAC (5).
It has long been known that thrombin possesses proinflammatory effects mediated by proteaseactivated receptor (PAR)-1 (6) and that both thrombin and FXa have profibrotic effects (7).
Furthermore, thrombin-inhibition has antifibrotic effects (8) . Atrial fibrosis is a major potential contributor to the substrate for AF maintenance (9, 10) , and therefore beyond its role in clotting, acti- 
RELATIONSHIP TO OTHER STUDIES IN THE LITERATURE
A range of other investigators have addressed the effects of OACs on atrial electrophysiology and remodeling, as summarized in Table 1 . Chang et al. (12) showed that thrombin decreases pulmonary vein (PV) cellular automaticity and left-atrial (LA) action potential duration (APD) while increasing PV triggered activity, effects that were blocked by dabigatran, a PAR-1 blocker and N(G)-nitro-L-arginine methyl ester (L-NAME) (a nitric oxide synthase inhibitor). An APD reduction should promote re-entry circuits that maintain AF, whereas increased triggered activity should enhance spontaneous AFinitiation (13) . In a follow-up study, the same investigators showed that rivaroxaban reduces LA APD in rabbit LA-cells, while increasing L-type Ca 2þ current and ultrarapid delayed rectifier K þ current (14) . If applicable to man, these results would suggest that thrombin promotes AF, an effect that can be prevented by a DTI, but that rivaroxaban might be pro- Changes in AF sustainability were not reported.
SYNTHESIS OF RESULTS TO DATE
Taken together, the available data suggest that the thrombosis-promoting effect of AF may, in addition to leading to thromboembolic events, contribute to the ability of AF to cause electrical and structural changes that favor its own maintenance and recurrence.
However, there are some aspects of the findings that are unclear. Two studies suggest direct electrophysiological effects of activated thrombin and OACs (12, 14) . This action should lead to detectable clinical electrophysiological and electrocardiogram changes in AF populations, but these have not been reported.
Promotion of the AF substrate in association with increased coagulation has been described in rodent models. For one of these, reversal by DTI was shown (11) , but for the other, DOAC effects were apparently not tested (16) . AF-promoting effects have been modest and reported only in rodent models. The stimulation of proinflammatory and profibrotic factors by activated thrombin and/or FXa seems to be a fairly constant finding, as is its inhibition by DOACs.
WHERE DO WE GO FROM HERE?
It will be very important to determine the relevance of these findings to atrial electrophysiology and remodeling in man. The data indicating that thrombin activation promotes atrial remodeling have been obtained principally in specific rodent models and in vitro cell systems (11, 16) for OAC treatment will certainly move even lower than it is today, and a new and attractive treatment to suppress AF will have been identified.
CONCLUSIONS
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